Yeon Jeong Kim
Overview
Explore the profile of Yeon Jeong Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
1873
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kim J, Kim H, Lee M, Lee H, Kim Y, Lee W, et al.
J Transl Med
. 2023 Mar;
21(1):209.
PMID: 36941605
Background: Previous investigations of transcriptomic signatures of cancer patient survival and post-therapy relapse have focused on tumor tissue. In contrast, here we show that in colorectal cancer (CRC) transcriptomes derived...
12.
Kim Y, Park K, Kim Y, Shin S, Kim Y, Choi C, et al.
Int J Mol Sci
. 2022 Dec;
23(24).
PMID: 36555180
Although the combination of radiotherapy and immunotherapy has proven to be effective in lung cancer treatment, it may not be sufficient to fully activate the antitumor immune response. Here, we...
13.
Sohn J, Choi M, Yi D, Menon V, Kim Y, Lee J, et al.
Nat Biomed Eng
. 2022 Dec;
7(7):853-866.
PMID: 36536253
Variant callers typically produce massive numbers of false positives for structural variations, such as cancer-relevant copy-number alterations and fusion genes resulting from genome rearrangements. Here we describe an ultrafast and...
14.
Kim D, Kim J, Lee J, Han S, Lee K, Kong J, et al.
iScience
. 2022 Nov;
25(11):105392.
PMID: 36345336
Predicting colorectal cancer recurrence after tumor resection is crucial because it promotes the administration of proper subsequent treatment or management to improve the clinical outcomes of patients. Several clinical or...
15.
Yoon S, Cho J, Kim Y, Kim S, Kim W
Clin Lymphoma Myeloma Leuk
. 2022 Aug;
22(11):e972-e980.
PMID: 35995702
Background: Based on specific epigenetic mutation in AITL such as TET2, DNMT3A, IDH2, and RHOA, hypomethylating agents are emerging as a promising treatment option for AITL. Method: The efficacy and...
16.
Kim Y, Jiang F, Park J, Jeong H, Baek J, Hong S, et al.
Front Pharmacol
. 2022 May;
13:890614.
PMID: 35600865
Pancreatic adenocarcinoma up-regulated factor (PAUF) plays an important role in tumor growth, metastasis, and immune evasion in the pancreatic tumor microenvironment, and recent studies suggest an association between PAUF expression...
17.
Bang Y, Shim J, Ryu K, Kim Y, Choi M, Yoon S, et al.
J Cancer
. 2022 Apr;
13(5):1388-1397.
PMID: 35371331
The clinical utility of mRNA cargo in exosomes is unclear, although exosomes have potential as non-invasive biomarkers. This study aimed to investigate the feasibility of exosomal mRNA sequencing for monitoring...
18.
Kim S, Kim Y, Yoon S, Ryu K, Park B, Park D, et al.
Cancer Res Treat
. 2022 Mar;
55(1):291-303.
PMID: 35240014
Purpose: Plasma circulating tumor DNA (ctDNA) could reflect the genetic alterations present in tumor tissues. However, there is little information about the clinical relevance of cell-free DNA genotyping in peripheral...
19.
Ku B, Kim Y, Park D, Lee S, Ahn J, Park K, et al.
Oncology
. 2022 Feb;
100(4):228-237.
PMID: 35196661
Objectives: During targeted therapy, tumor heterogeneity can drive the evolution of multiple tumor subclones harboring unique resistance mechanisms. Sequential profiling of plasma cell-free DNA (cfDNA) provides a noninvasive method for...
20.
Chun H, Lee M, Lee H, Oh S, Baek H, Moon J, et al.
Clin Gastroenterol Hepatol
. 2022 Jan;
21(2):358-369.e12.
PMID: 34998993
Background & Aims: International guidelines recommend physical activity for subjects with nonalcoholic fatty liver disease (NAFLD). This study investigated the association of physical activity with risk of liver fibrosis, sarcopenia,...